文献速递眼整形与眼眶

维莫德吉治疗眼眶及晚期眼周基底细胞癌的疗效

Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
PubMed 文献 · Am J Ophthalmol · 2019-05-09

这项回顾性病例系列评估了Hedgehog通路抑制剂维莫德吉治疗以色列2家三级医疗中心2012—2017年眼眶及晚期眼周基底细胞癌患者的效果。21例患者中,完全缓解10例、部分缓解10例、稳定1例;常见低级别不良反应为肌肉痉挛、味觉障碍、脱发和体重下降,8例因副作用停药。作者认为按个体化最大耐受剂量给药可能获得与ERIVANCE方案相当的缓解,需更长期研究评估预后。

要点

  • 21例眼眶或眼周基底细胞癌患者接受维莫德吉治疗,完全缓解10例、部分缓解10例、稳定1例。
  • 完全缓解者中5例在16个月时维持完全缓解,停药后复发的3例于8个月后复发。
  • 最常见1—2级不良反应为肌肉痉挛76%、味觉障碍57%、脱发47%、体重下降47%、食欲下降19%,3—4级仅肝毒性10%。

核心结论

  • 作者认为,这是据其所知在美国和欧洲以外开展的唯一研究,也是迄今关于维莫德吉治疗局部晚期眼周基底细胞癌规模最大的研究。
  • 作者认为按个体化最大耐受剂量给药可能获得与ERIVANCE方案相当的缓解。
  • 作者指出需更长期研究评估预后。

研究设计与样本

  • 回顾性病例系列,收集2012—2017年在以色列2家三级医疗中心接受维莫德吉治疗的局部晚期及转移性眼眶或眼周基底细胞癌患者的病历资料。
  • 队列共21例患者(男性16例),中位年龄76岁,眼周基底细胞癌6例、眼眶基底细胞癌15例。

主要发现

  • 中位治疗时长9个月,总体随访26个月(范围9—60个月),停药后随访17个月。
  • 临床缓解为完全缓解10例、部分缓解10例、稳定1例。
  • 完全缓解者中5例在16个月时维持完全缓解,停药后复发的3例于8个月后复发。
  • 几乎所有治疗相关不良反应为1级或2级(低级别)。
  • 5例死亡,多数死因与维莫德吉治疗无关,但1例可能死于治疗相关脓毒症(5级不良事件)。

关键数值与推荐

  • 最常见1级或2级不良反应:肌肉痉挛76%、味觉障碍57%、脱发47%、体重下降47%、食欲下降19%。
  • 唯一3级或4级不良事件为肝毒性10%。
  • 8例因副作用停药。

临床怎么用

  • 作者认为按个体化最大耐受剂量给药可能获得与ERIVANCE方案相当的缓解。
  • 作者指出需更长期研究评估预后。

局限性

  • 原文未报告局限性,但作者在结论中指出需更长期研究评估预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effectiveness of vismodegib, a Hedgehog pathway inhibitor, in treating orbital and advanced periocular basal cell carcinoma (BCC) in Israeli multidisciplinary medical centers. DESIGN: Retrospective case series. METHODS: Background, treatment, and outcome data were retrospectively collected from the medical records of all patients with locally advanced and metastatic orbital or periocular BCC treated with vismodegib in 2012-2017 at 2 tertiary medical centers. RESULTS: The cohort included 21 patients (16 male) of median age 76 years with periocular (n=6) or orbital (n=15) BCC. Median duration of treatment was 9 months, with follow-up of 26 months (range 9-60 months) overall and 17 months after treatment cessation. Clinical response was complete in 10 patients, partial in 10 patients, and stable in 1 patient. Among the complete responders, 5 maintained a complete response at 16 months, and 3 who stopped treatment had a recurrence 8 months later. Almost all treatment-related adverse reactions were graded 1 or 2 (low-grade). The most common grade 1 or 2 complications were muscle spasm (76%), followed by dysgeusia (57%), alopecia (47%), weight loss (47%) and decreased appetite (19%). The only grade 3 or 4 adverse event was hepatotoxicity (10%). Eight patients discontinued treatment because of side effects. Five patients died, most from reasons unrelated to vismodegib therapy, except for 1 patient who died from possibly treatment-related sepsis (grade 5 adverse event). CONCLUSIONS: To our knowledge, this is the only study generated outside the United States and Europe, and it represents the largest study to date on vismodegib therapy for locally advanced periocular BCC. Treatment according to an individualized maximally tolerated dose may achieve a comparable response to the ERIVANCE protocol. Longer-term studies are needed to assess prognosis.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Eiger-Moscovich M, Reich E, Tauber G, et al. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma. Am J Ophthalmol. 2019. PMID: 31077664. doi:10.1016/j.ajo.2019.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。